Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma

Por Barth, Matthew J., Mavis, Cory, Czuczman, Myron S., Hernandez-Ilizaliturri, Francisco J.
Publicado no Clin Cancer Res (2015)

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

Por Bhatti, Maria, Ippolito, Thomas, Mavis, Cory, Gu, Juan, Cairo, Mitchell S., Lim, Megan S., Hernandez-Ilizaliturri, Francisco, Barth, Matthew J.
Publicado no Oncotarget (2018)

Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents

Por Frys, Sarah, Simons, Zachary, Hu, Qiang, Barth, Matthew J., Gu, Juan J., Mavis, Cory, Skitzki, Joseph, Song, Liu, Czuczman, Myron S., Hernandez-Ilizaliturri, Francisco J.
Publicado no Br J Haematol (2015)

Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children’s Oncology Group (COG) report

Por Barth, Matthew J., Goldman, Stanton, Smith, Lynette, Perkins, Sherrie, Shiramizu, Bruce, Gross, Thomas G., Harrison, Lauren, Sanger, Warren, Geyer, Mark B., Giulino-Roth, Lisa, Cairo, Mitchell S.
Publicado em 2013

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Por Czuczman, Natalie M., Barth, Matthew J., Gu, Juan, Neppalli, Vishala, Mavis, Cory, Frys, Sarah E., Hu, Qiang, Liu, Song, Klener, Pavel, Vockova, Petra, Czuczman, Myron S., Hernandez-Ilizaliturri, Francisco J.
Publicado no Blood (2016)

A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential p...

Por Awasthi, Aradhana, Rolland, Delphine C.M., Ayello, Janet, van de Ven, Carmella, Basrur, Venkatesha, Conlon, Kevin, Fermin, Damian, Barth, Matthew J, Klein, Christian, Elenitoba-Johnson, Kojo S.J., Lim, Megan S., Cairo, Mitchell S.
Publicado no Oncotarget (2017)

Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: A Children’s Oncology Group Pilot Study Report...

Por Shiramizu, Bruce, Goldman, Stanton, Smith, Lynette, Agsalda-Garcia, Melissa, Galardy, Paul, Perkins, Sherrie L., Frazer, J. Kimble, Sanger, Warren, Anderson, James R., Gross, Thomas G., Weinstein, Howard, Harrison, Lauren, Barth, Matthew J., Mussolin, Lara, Cairo, Mitchell S.
Publicado no Br J Haematol (2015)

Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma

Por Giulino-Roth, Lisa, van Besien, Herman J., Dalton, Tanner, Totonchy, Jennifer E., Rodina, Anna, Taldone, Tony, Bolaender, Alexander, Erdjument-Bromage, Hediye, Sadek, Jouliana, Chadburn, Amy, Barth, Matthew J., Dela Cruz, Filemon S., Rainey, Allison, Kung, Andrew L., Chiosis, Gabriela, Cesarman, Ethel
Publicado no Mol Cancer Ther (2017)